InvestorWire NewsRoom

InvestorNewsBreaks

NewsBreak Category: Psychedelics
Monday Mar 11, 2024 - 10:43 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Takes First Step Toward Obtaining Permission for unbuzzd(TM) Phase-1b Clinical Trial

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has submitted a Clinical Trial Application (“CTA”) for its planned phase-1b clinical trial. According to the announcement, the trial will focus on evaluating the safety and efficacy of unbuzzd(TM) in healthy volunteers in an induced state of…

Continue Reading

Tuesday Mar 05, 2024 - 1:24 pm

InvestorNewsBreaks – Mushrooms Inc. (MSRM) Announces Latest Product Launches, Development Collaboration in Germany

Mushrooms (OTC: MSRM), a developing leader in biotechnology and sustainable healthcare innovation using mushrooms and mycelium, today announced a suite of strategic initiatives aimed at transforming the healthcare landscape. These efforts, which underscore Mushrooms Inc.’s commitment to innovation, sustainability and the advancement of global health, include the launch of two groundbreaking health supplements, LONGEVITY and SPORT+, as well as the exploration of a development collaboration…

Continue Reading

Tuesday Mar 05, 2024 - 10:49 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Presents Positive Results on First-in-Human Phase 1 Study of Lucid-MS

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced its participation in Americas Committee for Treatment and Research in Multiple Sclerosis (“ACTRIMS”) 2024 Forum. Held during Feb. 29 - Mar 2, 2024, in West Palm Beach, Florida, the annual conference is the largest MS event of its kind in North…

Continue Reading

Wednesday Feb 28, 2024 - 10:33 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Board of Directors Approves Debt Settlement

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has announced a debt settlement. According to the announcement, the company’s board of directors approved the settlement of $637,650 owed to arm's length creditors through issuing 545,000 Class B subordinate voting shares in the capital of the corporation; the shares were issued at…

Continue Reading

Monday Feb 26, 2024 - 11:41 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), Subsidiary Enter Agreement for Clinical Trial of Proprietary Blend Beverage

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, and its subsidiary, HUGE Biopharma Australia Pty Ltd., have entered into an agreement with Ingenu CRO Pty Ltd. The agreement outlines a study to assess the safety and efficacy of unbuzzd(TM), a fortified oral liquid formula, being used as a treatment with healthy…

Continue Reading

Tuesday Feb 20, 2024 - 10:27 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Market Offering Agreement

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has entered into an agreement. The market offering agreement is with H.C. Wainwright & Co. LLC. According to the agreement, FSD Pharma may offer and sell Class B subordinate voting shares in the capital of the company at its discretion. The offering may…

Continue Reading

Tuesday Feb 06, 2024 - 11:52 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Court of Appeal Dismisses Motion Brought by Dr. Raza Bokhari

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders. The company today announced that the Court of Appeal for Ontario affirmed the judgment entered by the Superior Court of Justice in the amount of CDN $2.81 million, plus $175,000, plus interest. FSD…

Continue Reading

Tuesday Jan 30, 2024 - 9:48 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Names New Board Member, Reports on Corporate Updates

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has appointed Dr. Sanjiv Chopra to its board of directors. According to the announcement. Chopra will be replacing Nitin Kaushal, who resigned from his position. A professor of medicine and former faculty dean for continuing medical education at Harvard Medical School, Dr. Sanjiv…

Continue Reading

Wednesday Jan 17, 2024 - 11:05 am

InvestorNewsBreaks – Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND) (FSE: CWY0) Selects Aegis Capital Corp. as Sole Bookrunner for $2.4M Private Placement

Clearmind Medicine (NASDAQ: CMND) (CSE: CMND) (FSE: CWY0), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, has chosen Aegis Capital Corp. to act as sole bookrunner on its registered direct and private placement. According to the announcement, the placement is valued at $2.4 million. In the wealth management and investment banking…

Continue Reading

Tuesday Jan 16, 2024 - 1:37 pm

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Provides Update on Litigation

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today provided an update regarding its litigation with GBB Drink Lab Inc. (“GBB”). In May 2023, GBB filed a lawsuit against FSD Pharma alleging a material breach of a mutual nondisclosure agreement and trade secret misappropriation. FSD Pharma has categorically denied these allegations…

Continue Reading

Tuesday Dec 05, 2023 - 2:38 pm

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Closes Non-Brokered Private Placement

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) today announced that it has closed a non-brokered private placement and issued 24 class A multiple voting shares of the company, each at a price of $1.90, for gross proceeds of $45.60 (the “offering”). All securities issued pursuant to the offering are subject to a statutory hold period of four months plus a day from issuance in…

Continue Reading

Thursday Nov 30, 2023 - 12:25 pm

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), Celly Nu Complete Plan of Arrangement

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) and Celly Nutrition Corp. (“Celly Nu”) today announced the closing of the previously proposed distribution of a portion of FSD Pharma’s holdings of common shares of Celly Nu (“Celly Nu shares”) to certain securityholders of FSD Pharma through a statutory plan of arrangement under section 182 of the Business Corporations Act (Ontario) (the “plan of arrangement”), per…

Continue Reading

Tuesday Nov 28, 2023 - 11:59 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Issues update on GBB Drink Lab Inc. Litigation and Safety Shot

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions. The company has issued a statement as an update regarding its litigation with GBB Drink Lab Inc. previously referenced at: FSD Pharma Rebuts Claims of GBB Drink Lab now acquired by Jupiter Wellness Inc. (NASDAQ: JUPW). In May of this year, GBB…

Continue Reading

Monday Nov 27, 2023 - 12:18 pm

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Featured in Goldman Small Cap Research Report, Receives Approval for Celly Nu Plan of Arrangement

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is spotlighted in a recent report released by Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors. The new report notes that through its wholly owned subsidiary, Lucid Psycheceuticals Inc., FSD is working to develop…

Continue Reading

Tuesday Nov 21, 2023 - 12:31 pm

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Approval of the Plan of Arrangement with Celly Nu

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that FSD Pharma securityholders (as defined in the announcement) have approved the previously disclosed plan of arrangement under section 182 of the Business Corporations Act (Ontario) pursuant to which common shares in the capital of Celly Nutrition Corp. (“Celly Nu”) will…

Continue Reading

Wednesday Nov 15, 2023 - 12:59 pm

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Filing of Supplement to Management Information Circular

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has filed a supplement related to certain restrictions on resale that will apply to the Celly Nu shares that will be distributed to the FSD Pharma securityholders. The company filed the supplement, dated Nov. 15, 2023, as an addition to the Management Information…

Continue Reading

Monday Oct 23, 2023 - 11:02 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Filing in Connection with Proposed Arrangement with Celly Nu

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions. Together with Celly Nutrition Corp. (“Celly Nu”), FSD Pharma today announced its filing on www.SEDARPlus.ca its management information circular and related materials in connection with the special meeting of FSD Pharma Securityholders (as defined in the company’s press release dated Oct. 5,…

Continue Reading

Wednesday Oct 18, 2023 - 11:38 am

InvestorNewsBreaks – Mushrooms Inc. (MSRM) Announces Patent Filing for Groundbreaking Mycelium Technology

Mushrooms (OTC: MSRM), a leader in mycelium research and development, today announced the successful filing of its non-provisional patent, titled “Method of Generating Multifunctional Mycelium Products.” The patent showcases a unique approach to bacterial detection and nutrient delivery, marking a significant shift from the company’s previous provisional filing. “With the phase 1 plan for our patent, we are channeling our efforts into a medical bandage…

Continue Reading

Wednesday Oct 04, 2023 - 1:03 pm

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Dismissal of Motion, Wins $2.8 Million Award

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, is reporting on the status of court action filed against it. The company announced that the Ontario Superior Court of Justice dismissed the motion to set aside an arbitration award to FSD Pharma;…

Continue Reading

Friday Sep 22, 2023 - 10:29 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Featured in InvestmentPitch Media Video

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a company building a portfolio of innovative assets and biotech solutions, was featured in an InvestmentPitch media video that discusses continued development of UNBUZZD(TM), the company’s new rapid detox drink. UNBUZZD(TM) is a proprietary formulation of natural ingredients, vitamins and minerals to help relieve the effects of alcohol consumption, such as inebriation, and restoring normal lifestyle. Kevin…

Continue Reading

Thursday Sep 14, 2023 - 1:47 pm

InvestorNewsBreaks – Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Collaborates to Unlock the Value of Brands Through Strategic Acquisitions

Lucy Scientific Discovery (NASDAQ: LSDI), a publicly traded company focused on the development, sale, delivery, and manufacturing of psychotropic products, recently announced the acquisition of BlueSky Wellness Inc., along with its portfolio of brands, which adds psychotropic products to its catalog and expands its footprint into the global wellness market. BlueSky wellness-focused ecommerce brands include Keoni, Keoni Sport, Blush Wellness and AMMA Healing, which, in…

Continue Reading

Wednesday Sep 13, 2023 - 10:12 am

InvestorNewsBreaks – Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Announces Acquisition of BlueSky Wellness, Expands Footprint in Global Wellness Market

Lucy Scientific Discovery (NASDAQ: LSDI), a publicly traded company focused on the development, sale, delivery and manufacturing of psychotropic products, is acquiring BlueSky Wellness Inc. and the BlueSky portfolio of brands. According to the announcement, the acquisition adds psychotropic products to the company’s catalog, enabling LSDI to expand its footprint in the global wellness market. BlueSky Wellness brands include Keoni, Keoni Sport, Blush Wellness and…

Continue Reading

Wednesday Sep 13, 2023 - 10:06 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Coverage Initiated by Singular Research

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders. The company today announced that Singular Research has initiated analyst coverage on FSD Pharma. The company has not paid for the research report prepared by Singular Research, and all reports on FSD Pharma…

Continue Reading

Tuesday Sep 12, 2023 - 10:00 am

InvestorNewsBreaks – Lucy Scientific Discovery Inc. (NASDAQ: LSDI) to Acquire BlueSky Wellness Inc. in All-Stock Transaction

Lucy Scientific Discovery (NASDAQ: LSDI) is the leader in the psychotropic industry, which recently celebrated the acquisition of the intellectual property of High Times, the most iconic brand in the cannabis industry. Today the company announced an agreement to acquire BlueSky Wellness Inc. and its portfolio of brands, expanding Lucy’s footprint into the growing global wellness category by adding psychotropic products to its capabilities. BlueSky…

Continue Reading

Friday Sep 08, 2023 - 11:58 am

InvestorNewsBreaks – Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Strengthening Position in Projected $51B Global Cannabis Market

Lucy Scientific Discovery (NASDAQ: LSDI) is featured in a recent FinancialNewsMedia (“FNM”) Editorial. The editorial provides an overview of LSDI’s position in a global cannabis market projected to hit $51 billion this year. According to the press release, the global cannabis market has seen consistent growth year after year, with increasing legalization of cannabis fueling that growth. The release notes that a recent Statista report…

Continue Reading

Thursday Sep 07, 2023 - 11:04 am

InvestorNewsBreaks – Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Acquires High Times Intellectual Property, Featured in Financial News Media Article

Lucy Scientific Discovery (NASDAQ: LSDI) today announced the acquisition of the intellectual property (“IP”) of High Times, an iconic brand in the cannabis industry. In addition to the Hightimes.com domain, the transaction also includes the trademarks for the Cannabis Cup and 420.com brands and their respective domain names. In exchange, High Times will receive a 19.9% stake in Lucy's outstanding stock as well as performance-based…

Continue Reading

Wednesday Aug 23, 2023 - 12:18 pm

InvestorNewsBreaks – Mushrooms Inc. (MSRM) Assembles Business Development Team to Catapult Growth

Mushrooms Inc. (OTC: MSRM) today announced its newly formed business development team, strategically assembled to harness the momentum generated by the company’s new technology and Innovation lab development. The team is comprised of accomplished professionals with diverse backgrounds and poised to drive Mushrooms Inc. into a new era of innovation and growth. “This enhanced business development team represents a pivotal milestone for Mushrooms Inc.,” said…

Continue Reading

Thursday Aug 03, 2023 - 3:06 pm

InvestorNewsBreaks — Green Label Summit 2023 to Showcase Insights and Innovations Shaping the Future of Cannabis

The highly-anticipated Green Label Summit 2023, hosted by Jotia Group, is set to shine in the shimmering lights of Las Vegas on Sept. 13 - 14 at The Expo, World Market Center. The event is designed to deliver an unparalleled platform for dynamic discussions and visionary insights into the ever-evolving cannabis industry. The summit will feature the Psychedelic Horizons Forum, captivating sessions and masterclasses, with…

Continue Reading

Wednesday Aug 02, 2023 - 10:34 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Agreement to Launch UNBUZZD

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders. The company today announced its entry into a definitive agreement with Celly Nutrition Inc. to grant exclusive rights to recreational applications for FSD Pharma’s alcohol misuse technology and launch UNBUZZD. A revolutionary, rapid…

Continue Reading

Wednesday Aug 02, 2023 - 10:16 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Details About Public Offering, Begins Dosing in Final Phase 2 Trial Cohort

Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is reporting the price and size of the public offering it announced earlier this week. According to the company, 24,264,706 units of the company will be sold at a price of $0.34 per unit, resulting in an estimated $8.25 million in gross…

Continue Reading

Wednesday Jul 19, 2023 - 12:16 pm

InvestorNewsBreaks – Mushrooms Inc. (MSRM) Featured in Psychedelic Spotlight Podcast

Mushrooms Inc. (OTC: MSRM) today announced that the company’s CEO Kimberly Carlson recently appeared on the esteemed Psychedelic Spotlight Podcast to discuss the exciting potential of the industrial mushroom industry. Mushrooms Inc., the first company trading on the U.S. stock market focused on the industrial side of mushrooms, is leading the way in revolutionizing this emerging sector. During the podcast episode hosted by David Flores,…

Continue Reading

Tuesday Jul 18, 2023 - 10:11 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Reports Arbitration Panel Finding in Syneos Health (NASDAQ: SYNH) Proceeding

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, is reporting that an arbitration panel has found that Syneos Health (NASDAQ: SYNH) failed to use commercially reasonable efforts in conducting its trial for FSD 201. According to the announcement, Syneos Health filed…

Continue Reading

Friday Jun 30, 2023 - 1:32 pm

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Shares Results Shareholder Annual General and Special Meeting

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, recently held its annual general and special meeting of shareholders. The virtual-only meeting was held on June 29, 2023. The company is reporting on the results of the meeting, including the election of…

Continue Reading

Friday Jun 23, 2023 - 1:42 pm

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Working to Deliver Novel Treatment for Chronic Pain Sufferers

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, recently announced a new research and development agreement to create a time-release ketamine implant to treat fibromyalgia and other chronic pain conditions. Silo intends to leverage its existing partnerships with academic research institutions to help move the novel treatment for chronic pain sufferers through the Food and Drug…

Continue Reading

Friday Jun 23, 2023 - 12:06 pm

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) Featured in InvestmentPitch Media Video

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, was featured in a video published by InvestmentPitch Media. FSD Pharma recently entered into a non-binding letter of intent with 1319741 B.C. Ltd., an unlisted reporting issuer, which will be renamed Celly Nutrition Inc. FSD…

Continue Reading

Wednesday Jun 21, 2023 - 2:13 pm

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Secures US Patent for SPU-21 Treatment for Autoimmune Disease

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that the U.S. Patent and Trademark Office (“USPTO”) has issued U.S. Patent 16/825,371 titled “Peptide-Targeted Liposomal Delivery for Treatment, Diagnosis and Imaging of Diseases and Disorders.” According to the announcement, the new patent claims cover the company’s portfolio drug SPU-21, a peptide-guided anti-arthritis drug, as a…

Continue Reading

Tuesday Jun 20, 2023 - 11:56 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Agreement to Grant Exclusive Rights to Recreational Alcohol Misuse Technology

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced its entry into a non-binding letter of intent. The agreement, dated June 19, 2023, is with 1319741 B.C. Ltd., which will be renamed “Celly Nutrition Inc.” (“Celly Nu”), an unlisted reporting…

Continue Reading

Thursday May 25, 2023 - 1:04 pm

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Board Appointment of Dr. Eric Hoskins

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders. The company today announced the appointment of Dr. Eric Hoskins to its board of directors. A medical doctor, Dr. Hoskins is specialized in public health and presently a partner at Maverix Private…

Continue Reading

Wednesday May 24, 2023 - 11:40 am

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Initiates Dosing of First Participants in Phase 1 Clinical Trial

Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options. The company today announced that the first participants have been dosed with CYB004 in its ongoing three-part phase 1 clinical trial evaluating intravenous N,N-dimethyltryptamine (“IV DMT”) and CYB004 in healthy volunteers. No safety concerns were reported from the initial participants…

Continue Reading

Tuesday May 16, 2023 - 11:10 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Featured in InvestmentPitch Media Video

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders. The company has been awarded approximately C$2.81 million in an arbitration settlement. An InvestmentPitch Media video provides additional information about this news and the company. The video is available for viewing on…

Continue Reading

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).